$3.05
+2.7%Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Chairman, Chief Executive Officer & President
Compensation
$598,048
Chief Financial Officer and Principal Financial & Accounting Officer
Chief Medical Officer
Chief Technical Officer
Compensation
$363,048
General Counsel & Corporate Secretary
Compensation
$380,000
Senior Vice President of Clinical Development
Compensation
$242,615
Vice President & Head of Regulatory Affairs
During the last 12 months, insiders have purchased $3.29M and sold $7.21M worth of GNLX shares, resulting in $3.91M of net selling activity.
0
0.00
20.3K
56.91K
-57K
-$57K
0
0.00
10.0K
28.96K
-29K
-$29K
0
0.00
16.0K
82.06K
-82K
-$82K
904.9K
3.29M
498.3K
7.04M
-3.7M
-$3.75M
Zindrick Thomas
Officer: President And Ceo
$1.74M
Cappello Joseph
Officer: Chief Technical Officer
$519K
Yu Yong
Officer: Svp, Clinical Development
$490K
Smalling Ralph
Officer: Head Of Regulatory
$127K
Tyree James L
Director
$104K
Zindrick Thomas
Officer: President And Ceo
$5.68M
Yu Yong
Officer: Chief Scientific Officer
$1.27M
Thomas John
Director
$109K
Cappello Joseph
Officer: Chief Technical Officer
$88K
Smalling Ralph
Officer: Head Of Regulatory
$61K
Negative insider sentiment with $3.91M net selling. Selling notably exceeds buying, warranting closer scrutiny of company fundamentals.
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
GNLX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | July 11, 2025 | July 11, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | June 14, 2024 | June 14, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | July 20, 2023 | July 20, 2023 | 2023 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.